直 Japanese PDF Font
  • 我们的专业人员
  • 服务
  • 我们的见解
  • 办公室
  • 事务所
  • 人才招聘
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • 生命科学
    • Transportation and Logistics
  • 经验

制药

About

制药 是本所业务分支,下属于 生命科学.

突破性的发现和创新需要强有力的保护

人类对制药行业寄予厚望,希望他们研制出挽救生命的新药和改善生活质量的治疗方法。但是,即使投入数十亿美元的研发资金,实际能通过临床试验和监管机构严格的上市批准程序的药物却寥寥无几。因此,新药一旦成功上市,公司必须采取措施,保护与新药及治疗方法有关的知识产权。飞翰长期与富有创新精神的制药企业合作,协助他们保护和充分利用自己宝贵的知识产权资产,制定申办路径策略与专利组合规划。

精通法律、科学与技术

飞翰客户的业务和知识产权资产遍布全球,在各司法管辖区保护资产的挑战性日益上升。飞翰在世界各地设有代表处,经常与跨国企业合作,拥有必要的资源与经验,能够协助制药企业制定和执行全球策略。由于新发明及其商业应用的迅速发展,律师事务所必须全面掌握与知识产权有关的法律问题,并具备相关行业视野与见解,才能理解与这类发展有关的科学与策略问题。

我们具有为制药客户处理过几乎所有类型知识产权问题的经验,协助企业:

  • 代表客户参与复杂的制药专利侵权及商业秘密案件,以及《韦克斯曼法》 (Hatch-Waxman Act)诉讼。
  • 由经验丰富的审判和上诉团队在地区法院和上诉法院为高价值产品代理诉讼;
  • 制定与执行申办策略,保护客户的产品并分析竞争对手的产品,确保客户实现其知识产权资产的价值。
  • 起草和谈判许可协议,评估竞争对手专利的许可价值并指导客户作出许可决策。
  • 为并购及合作事宜提供尽职调查。
  • 就与商业有关的问题提供咨询服务,包括反垄断和竞争问题。
  • 在复杂的专利干预审查中确定优先事项。
  • 就诉讼策略提供建议,并在诉讼中主张和保护专利。
  • 提供商标申办与咨询服务。

我们与客户在众多领域合作、创新、推进科学,包括:

  • 抗体疗法-小分子和大分子
  • 非典型抗精神病药物
  • 缓释制剂
  • 疫苗

该行业领域内的专业人员

经验

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products*

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products.

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias*

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias.

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers*

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers.

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company*

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company.

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief*

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief.

Advised a biopharmaceutical company on patents covering a well-known biologic medicine for treating multiple types of cancer*

Advised a biopharmaceutical company on patents covering a well-known biologic medicine for treating multiple types of cancer.

More

专业见解

Conference

Georgia Life Sciences Summit 2026

August 25-26, 2026

Sandy Springs

At the PTAB Blog

Squires Issues Precedential Decision Clarifying Obviousness-Type Double Patenting Rejections

August 17, 2026

Conference

13th Annual Summit for Women Leaders in Life Sciences Law

July 29-30, 2026

Boston

Conference

2026 China Pharmaceutical Innovation Conference

July 22-24, 2026

Shanghai

Federal Circuit IP Blog

“2” Does Not Provide Written Description Support for “1”: Federal Circuit Affirms District Court’s Invalidation of Patent

July 8, 2026

Articles

Genus Claiming (Including Means Plus Function “MPF” Claiming) in Biotech and Pharma: Doctrinal Trajectory and Drafting Strategies

June 2026

More

近期活动

Conference

Life Sciences Patent Network North America Fall 2026

November 2-3, 2026

San Francisco

Conference

LES 2026 Annual Meeting

October 18-21, 2026

San Diego

新闻

Award/Ranking

Fourteen Finnegan Attorneys Named to the 2026 IAM Strategy 300 List

August 13, 2026

Award/Ranking

Partner Jeffrey M. Jacobstein Named Finalist for New England Legal Awards

August 10, 2026

Award/Ranking

Finnegan Shortlisted in 13 Categories at the 2026 LMG Life Sciences America Awards

July 15, 2026

Commentary

Finnegan Taps Partner from Kirkland to Boost IP Team

June 12, 2026

Media Mention

Finnegan Hires Kirkland & Ellis Litigator for London Office

June 8, 2026

Commentary

Finnegan Hires Kirkland Partner as It Eyes UK Growth

June 8, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • 隐私
  • 免责申明
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP